SurgePays, Inc. (SURG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 22, 2026, by SurgePays, Inc., a Nevada corporation. The report details a material definitive agreement entered into on January 20, 2026, regarding an underwritten public offering of common stock. The company is listed on The Nasdaq Stock Market LLC under the symbol "SURG."
Key Financial Metrics and Transaction Details
- Offering Size: 2,000,000 shares of common stock.
- Offering Price: $1.25 per share.
- Gross Proceeds: Approximately $2.5 million (before underwriting discounts and expenses).
- Over-Allotment Option: The underwriter, R.F. Lafferty & Co., Inc., holds a 45-day option to purchase up to an additional 300,000 shares.
- Representative's Warrants: Warrants issued to the underwriter to purchase 3.0% of the total shares sold, with an exercise price of 110% of the public offering price ($1.375).
- Use of Proceeds: Expansion of the Lifeline business, working capital, and general corporate purposes.
- Other Financial Data: The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Agreements
The primary material change is the execution of the Underwriting Agreement for the equity offering. Additionally, the company amended its At-The-Market (ATM) Sales Agreement with Titan Partners Group LLC. The amendment updates the eligible shares for sale under the ATM program to have an offering price of up to $1, excluding $1,775,390.79 of shares already sold under the prior prospectus through January 20, 2026.
Guidance, Outlook, and Restrictions
- Lock-Up Agreements: Directors and executive officers are restricted from selling securities for 180 days following the Underwriting Agreement date.
- Issuance Restrictions: The company agreed not to issue or announce the issuance of any capital stock or convertible securities for 180 days from the Closing Date without the underwriter's consent.
- Right of First Refusal: The underwriter was granted a three-month right of first refusal to act as the sole managing underwriter for future equity, equity-linked, or debt offerings.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks and uncertainties that could cause actual results to differ from projections.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and offering expenses.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific indemnification and covenant details.
- Confirm the status of the over-allotment option and whether the additional 300,000 shares were exercised.
- Examine the amended ATM Sales Agreement to understand the remaining capacity for share sales at the $1 price point.
- Check subsequent filings for any updates on the deployment of proceeds into the Lifeline business expansion.